RankingsPricing
  1. US-listed companies
  2. Citius Pharmaceuticals, Inc.
  3. Financials
  4. Cash from operations

Citius Pharmaceuticals, Inc.CTXR

Market cap
$10.7M
P/E ratio
SummaryFinancials
Period EndCash from operations (Million USD)YoY (%)
Sep 30, 2024-28-2.96%
Sep 30, 2023-29+2.46%
Sep 30, 2022-28+16.95%
Sep 30, 2021-24+43.23%
Sep 30, 2020-17+36.12%
Sep 30, 2019-12+9.89%
Sep 30, 2018-11+41.99%
Sep 30, 2017-8+35.10%
Sep 30, 2016-6+147.35%
Sep 30, 2015-2+11477.44%
Sep 30, 2013-0+1.38%
Sep 30, 2012-0-2.20%
Sep 30, 2011-0

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)